Clinical trials: Bronchial Neoplasms
Non Small Cell Lung Cancer
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NSCLC (NCT00583830)
- Testing
- Mapatumumab, Paclitaxel, Carboplatin
- Where
- 33 sites in United States, Germany and 2 more
- Volunteers
- 111 people
- Sponsor
- Human Genome Sciences Inc.
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-small cell lung cancer.
- Trial name
- NCT05242965
- Testing
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Non-Small Cell Lung Cancer (NSCLC)
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02521051
- Testing
- Alectinib, Bevacizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Stage IV NSCLC
Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer
This study is for patients with advanced non small cell lung cancer that has progressed despite standard of care. The purpose of the study is to see if Kanglaite injection has any effect on survival.
- Trial name
- NCT01640730
- Testing
- Kanglaite Injection
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- KangLaiTe USA
Non-small Cell Lung Cancer
Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC
Pemetrexed is an FDA-approved treatment for advanced lung cancer but the response rate is still very low. Bortezomib is currently approved to treat myeloma in patients who have already been treated.
- Trial name
- NCT00516100
- Testing
- bortezomib
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Aptium Oncology Research Network
Advanced Non Small Cell Lung Cancer
Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer
In France, lung cancer is responsible for more than 30000 each year. Progress was made in treatment of lung cancer in the last five years due to targeted therapies and to strategical evolutions consisting in a best adjustment of…
- Trial name
- NCT01631136
- Testing
- Cisplatin, Pemetrexed, Gemcitabine
- Where
- 91 sites in France
- Volunteers
- 932 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Carcinoma, Non-small Cell Lung
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
The purpose of this study is to establish whether patients with malignancy harboring a discoidin domain receptor 2 mutation or an inactivating B-RAF mutation will respond to dasatinib.
- Trial name
- NCT01514864
- Testing
- Dasatinib
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 19 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.
In this study, up to 21 patients with lung cancer will receive UV1 (a therapeutic synthetic peptide vaccine) at different dose levels. The safety and tolerability of UV1 as well as immunological response will be assessed.
- Trial name
- UV1-hTERT2012L (NCT01789099)
- Testing
- UV1 synthetic peptide vaccine and GM-CSF
- Where
- Norway
- Volunteers
- 18 people
- Sponsor
- Ultimovacs ASA
Non Small Cell Lung Cancer
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
- Trial name
- NCT01573702
- Testing
- Stereotactic Radiosurgery, Erlotinib
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
This randomized phase II trial is studying topotecan to see how well it works when given with or without aflibercept in treating patients with extensive-stage small cell lung cancer.
- Trial name
- NCT00828139
- Testing
- ziv-aflibercept, topotecan hydrochloride
- Where
- 257 sites in United States
- Volunteers
- 189 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC
This observational study is designed to assess the long term safety of the durvalumab treatment period including subsequent treatment period and demonstrate the efficacy of patients treated with durvalumab following…
- Trial name
- AYAME (NCT03995875)
- Where
- 43 sites in Japan
- Volunteers
- 529 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
For patients of advanced NSCLC (non small cell lung cancer) , Individualized cancer therapy has been widely accepted since the success of crizotinib administration based on EML4-ALK fusion gene detection and gefitinib and…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation, EGFR-TKI Sensitizing Mutation, Germline Mutations
- Trial name
- NCT01994057
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sun Yat-sen University
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Lung Cancer
PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies
The objective of the study is to prospectively generate real-life data in patients aged ≥70 years treated in first line for a thoracic tumor (Non-Small-Cell Lung Carcinoma) according to best standard of care as defined by the…
- Trial name
- PROMETHEE (NCT06646471)
- Testing
- Bio-bank repository, Quality of Life (QoL), G-Code
- Where
- 41 sites in France
- Volunteers
- 500 people
- Sponsor
- GFPC Investigation
Non Small Cell Lung Cancer
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people…
- Trial name
- NCT00347412
- Testing
- Paclitaxel, NOV-002, Carboplatin
- Where
- 75 sites in United States, Canada and 10 more
- Volunteers
- 903 people
- Sponsor
- Cellectar Biosciences, Inc.
Carcinoma, Non-Small-Cell Lung
Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This is a randomized, open- label, parallel group, phase IV, multicentre study. The total number of patients expected to be recruited is 40.
- Trial name
- NCT00536107
- Testing
- Gefitinib, CT or MRI, Docetaxel
- Where
- Taiwan
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma
Currently the investigators have two different classes of second-line treatment options in recurrent non-small Cell Lung Cancer (NSCLC).
- Trial name
- NCT00903292
- Testing
- erlotinib (Tarceva), pemetrexed (Alimta)
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- National Cheng-Kung University Hospital
Small Cell Lung Carcinoma
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Small cell lung cancer (SCLC), characterized by rapid proliferation, high growth fraction and early development of metastases, is the most aggressive form of lung cancer.
- Trial name
- ARSENAL (NCT05683977)
- Testing
- durvalumab
- Where
- 34 sites in France
- Volunteers
- 254 people
- Sponsor
- AstraZeneca
Esophageal Cancer, Head and Neck Cancer
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Precancerous Condition
- Trial name
- NCT00900419
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis, sputum cytology
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- University of Colorado, Denver
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.